JEOZIF PHARMA: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
JEOZIF PHARMA
Largest movements
- Receivables within one year +€38,948
up €38,948 (+238%), from €16,364 to €55,312
of which Trade receivables: +€38,794
- Reserves +€21,263
up €21,263 (+14.2%), from €149,988 to €171,251
of which Distributable reserves: +€21,263
- Other debts +€11,267
up €11,267 (+3.4%), from €329,538 to €340,805
- Trade debts +€10,085
up €10,085 (+1,530%), from €659 to €10,744
of which Bills of exchange payable: +€10,164
- Tax, wage and social debts -€5,896
down €5,896 (-37.3%), from €15,803 to €9,907
of which Taxes: -€5,908
- Gross operating margin +€1,235
up €1,235 (+4.3%), from €28,876 to €30,111
- Taxes +€869
up €869 (+11.5%), from €7,536 to €8,405
- Financial charges -€488
down €488 (-89.4%), from €546 to €58
From the 2023 result to the 2024 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2023 and 2024 balance sheets and the 2024 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2023 | 2024 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €502,188 | €538,907 | +€36,719 | +7.3% |
| Fixed assets | 21/28 | €480,723 | €480,723 | = | 0.0% |
| Financial fixed assets | 28 | €480,723 | €480,723 | = | 0.0% |
| Current assets | 29/58 | €21,465 | €58,184 | +€36,719 | +171% |
| Amounts receivable within one year | 40/41 | €16,364 | €55,312 | +€38,948 | +238% |
| Trade receivables | 40 | €12,826 | €51,620 | +€38,794 | +302% |
| Other amounts receivable | 41 | €3,538 | €3,692 | +€154 | +4.4% |
| Cash at bank and in hand | 54/58 | €5,101 | €2,872 | -€2,229 | -43.7% |
| Total equity and liabilities | 10/49 | €502,188 | €538,907 | +€36,719 | +7.3% |
| Equity | 10/15 | €156,188 | €177,451 | +€21,263 | +13.6% |
| Contributions | 10/11 | €6,200 | €6,200 | = | 0.0% |
| Reserves | 13 | €149,988 | €171,251 | +€21,263 | +14.2% |
| Non-distributable reserves | 130/1 | €1,860 | €1,860 | = | 0.0% |
| Reserves not available under the articles | 1311 | €1,860 | €1,860 | = | 0.0% |
| Distributable reserves | 133 | €148,128 | €169,391 | +€21,263 | +14.4% |
| Amounts payable | 17/49 | €346,000 | €361,456 | +€15,456 | +4.5% |
| Amounts payable within one year | 42/48 | €346,000 | €361,456 | +€15,456 | +4.5% |
| Trade debts | 44 | €659 | €10,744 | +€10,085 | +1,530% |
| Suppliers | 440/4 | €659 | €580 | -€79 | -12.0% |
| Bills of exchange payable | 441 | - | €10,164 | +€10,164 | |
| Taxes, remuneration and social security | 45 | €15,803 | €9,907 | -€5,896 | -37.3% |
| Taxes | 450/3 | €15,803 | €9,895 | -€5,908 | -37.4% |
| Remuneration and social security | 454/9 | - | €12 | +€12 | |
| Other amounts payable | 47/48 | €329,538 | €340,805 | +€11,267 | +3.4% |
| Other operating charges | 640/8 | €348 | €385 | +€37 | +10.6% |
| Gross operating margin | 9900 | €28,876 | €30,111 | +€1,235 | +4.3% |
| Operating profit (loss) | 9901 | €28,528 | €29,726 | +€1,198 | +4.2% |
| Financial income | 75/76B | €2 | - | -€2 | |
| Recurring financial income | 75 | €2 | - | -€2 | |
| Financial charges | 65/66B | €546 | €58 | -€488 | -89.4% |
| Recurring financial charges | 65 | €546 | €58 | -€488 | -89.4% |
| Profit (loss) for the period before taxes | 9903 | €27,984 | €29,668 | +€1,684 | +6.0% |
| Income taxes | 67/77 | €7,536 | €8,405 | +€869 | +11.5% |
| Profit (loss) for the period | 9904 | €20,448 | €21,263 | +€815 | +4.0% |
| Profit (loss) for the period to be appropriated | 9905 | €20,448 | €21,263 | +€815 | +4.0% |
Source: filed annual accounts (NBB), financial years ended 31 March 2023 and 31 March 2024. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 28 October 2026 via checked.be.